The Effect of Remdesivir for The Treatment of COVID-19 on Mortality Among Hospitalized Patients

Remdesivir's effectiveness for reducing in-hospital mortality in COVID-19 patients was contested in early observational studies due to methodological limitations including immortal time bias and failure to account for time-varying treatment.

Target RWE researchers analyzed hospital chargemaster data using rigorous causal methods to estimate the effect of remdesivir on in-hospital mortality, addressing key biases that had compromised earlier studies and stratifying results by oxygen supplementation level.

Providing a causally rigorous estimate of remdesivir's real-world effectiveness on in-hospital mortality supports Gilead's post-authorization evidence strategy and demonstrates the value of Target RWE's causal inference-first approach.

Causally rigorous remdesivir effectiveness evidence for in-hospital COVID-19 mortality reduction, Post-authorization real-world effectiveness evidence supporting Gilead remdesivir label strategy